Alteration of ribosome function upon 5-fluorouracil treatment favours cancer cell drug-tolerance
Therizols, G.; Bash-Imam, Z.; Panthu, B.; Machon, C.; Vincent, A.; Nait Slimane, S.; Garcia, M.; Laforets, F.; Marcel, V.; Boubaker-Vitre, J.; Souahlia, G.; Albaret, M.-A.; Mertani, H. C.; Prudhomme, M.; Bertrand, M.; Saurin, J.-C.; Bouvet, P.; Ohlmann, T.; Guitton, J.; Dalla Venezia, N.; Pannequin, J.; Catez, F.; Diaz, J.-J.
Show abstract
Partial response to chemotherapy leads to disease resurgence. Upon treatment, a subpopulation of cancer cells, called drug-tolerant persistent cells, display a transitory drug tolerance that lead to treatment resistance 1,2. Though drug-tolerance mechanisms remain poorly known, they have been linked to non-genomic processes, including epigenetics, stemness and dormancy 2-4. 5-fluorouracil (5-FU), the most widely used chemotherapy in cancer treatment, is associated with resistance. While prescribed as an inhibitor of DNA replication, 5-FU alters all RNA pathways 5-9. Here, we show that 5-FU treatment leads to the unexpected production of fluorinated ribosomes, exhibiting altered mRNA translation. 5-FU is incorporated into ribosomal RNAs of mature ribosomes in cancer cell lines, colorectal xenografts and human tumours. Fluorinated ribosomes appear to be functional, yet, they display a selective translational activity towards mRNAs according to the nature of their 5-untranslated region. As a result, we found that sustained translation of IGF-1R mRNA, which codes for one of the most potent cell survival effectors, promoted the survival of 5-FU-treated colorectal cancer cells. Altogether, our results demonstrate that "man-made" fluorinated ribosomes favour the drug-tolerant cellular phenotype by promoting translation of survival genes. This could be exploited for developing novel combined therapies. By unraveling translation regulation as a novel gene expression mechanism helping cells to survive a drug-challenge, our study extends the spectrum of molecular mechanisms driving drug-tolerance.
Matching journals
The top 3 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- H2AX promotes replication fork degradation and chemosensitivity in BRCA-deficient tumours 97%
- SMARCA4 deficient tumours are vulnerable to KDM6A/UTX and KDM6B/JMJD3 blockade 97%
- ANP32E drives vulnerability to ATR inhibitors by inducing R-loops-dependent Transcription Replication Conflicts in Triple Negative Breast Cancer 97%
Similar papers in this journal
Similar papers in this journal
- Extracellular 2’3’-cGAMP is an immunotransmitter produced by cancer cells and regulated by ENPP1 97%
- Non-oncology drugs are a source of previously unappreciated anti-cancer activity 96%
- Spatial proteomic characterization of HER2-positive breast tumors through neoadjuvant therapy predicts response 96%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.